Abstract
Tacrolimus is an immunosuppression drug widely used for prevention of allograft rejection in kidney and liver transplantations. The once-daily extended-release tacrolimus (LCP-Tac) is a novel formulation for tacrolimus, differentiated by using the MeltDose technology which was designed to enhance the bioavailability of drugs with low water solubility. This study assessed the economic impact of the use LCP-Tac compared with other once-daily extended-release tacrolimus (PR-Tac) and with twice-daily immediate-release tacrolimus (IR-Tac) in patients with kidney or liver transplantation.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
